Literature DB >> 16723176

Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine.

Patricia Gorak-Stolinska1, Rosemary E Weir, Sian Floyd, Maeve K Lalor, Sally Stenson, Keith Branson, Rose Blitz, Sarah Luke, Bernadette Nazareth, Anne Ben-Smith, Paul E M Fine, Hazel M Dockrell.   

Abstract

The immunogenicity and reactogenicity, in British schoolchildren, of the newly introduced Danish-SSI 1331 BCG vaccine was compared with that of the previously used Glaxo-Evans 1077 BCG vaccine. Interferon-gamma (IFN-gamma) response to M. tuberculosis purified protein derivative (M.tb PPD) in a 6-day whole blood assay and delayed type hypersensitivity (DTH) to tuberculin PPD were determined before and 1 year after receiving BCG or no vaccination. Scar size was measured 1 year after vaccination. There was no evidence of a difference in immunogenicity (IFN-gamma and DTH conversion rates) but evidence of lower reactogenicity (scar size) with Danish-SSI 1331 compared to Glaxo-Evans 1077 vaccines.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16723176     DOI： 10.1016/j.vaccine.2006.04.037

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  10 in total

1.  A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents.

Authors:  Chelsea Carpenter; John Sidney; Ravi Kolla; Kaustuv Nayak; Helena Tomiyama; Claudia Tomiyama; Oscar A Padilla; Virginie Rozot; Syed F Ahamed; Carlos Ponte; Valeria Rolla; Paulo R Antas; Anmol Chandele; John Kenneth; Seetha Laxmi; Edward Makgotlho; Valentina Vanini; Giuseppe Ippolito; Alexandra S Kazanova; Alexander V Panteleev; Willem Hanekom; Harriet Mayanja-Kizza; David Lewinsohn; Mayuko Saito; M Juliana McElrath; W Henry Boom; Delia Goletti; Robert Gilman; Irina V Lyadova; Thomas J Scriba; Esper G Kallas; Kaja Murali-Krishna; Alessandro Sette; Cecilia S Lindestam Arlehamn
Journal:  Tuberculosis (Edinb)       Date:  2015-08-01       Impact factor: 3.131

2.  Strain-dependent variation in Mycobacterium bovis BCG-induced human T-cell activation and gamma interferon production in vitro.

Authors:  Ana M Aguirre-Blanco; Pauline T Lukey; Jacqueline M Cliff; Hazel M Dockrell
Journal:  Infect Immun       Date:  2007-03-26       Impact factor: 3.441

3.  Immunogenicity of BCG in HIV-exposed and non-exposed infants following routine birth or delayed vaccination.

Authors:  A C Hesseling; H B Jaspan; G F Black; N Nene; G Walzl
Journal:  Int J Tuberc Lung Dis       Date:  2015-04       Impact factor: 2.373

4.  Construction and Characterization of the Mycobacterium tuberculosis sigE fadD26 Unmarked Double Mutant as a Vaccine Candidate.

Authors:  Rogelio Hernandez-Pando; Sung Jae Shin; Simon Clark; Stefano Casonato; Martin Becerril-Zambrano; Hongmin Kim; Francesca Boldrin; Dulce Mata-Espinoza; Roberta Provvedi; Ainhoa Arbues; Brenda Marquina-Castillo; Laura Cioetto Mazzabò; Jorge Barrios-Payan; Carlos Martin; Sang-Nae Cho; Ann Williams; Riccardo Manganelli
Journal:  Infect Immun       Date:  2019-12-17       Impact factor: 3.441

Review 5.  Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis.

Authors:  C Sander; H McShane
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

6.  Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response.

Authors:  Benjamin M N Kagina; Brian Abel; Mark Bowmaker; Thomas J Scriba; Sebastian Gelderbloem; Erica Smit; Mzwandile Erasmus; Nonhlanhla Nene; Gerhard Walzl; Gillian Black; Gregory D Hussey; Anneke C Hesseling; Willem A Hanekom
Journal:  Vaccine       Date:  2009-07-17       Impact factor: 3.641

7.  Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG).

Authors:  Richard Copin; Mireia Coscollá; Sebastien Gagneux; Joel D Ernst; Efstratios Efstathiadis
Journal:  Vaccine       Date:  2014-09-06       Impact factor: 3.641

8.  The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda.

Authors:  Elizabeth J Anderson; Emily L Webb; Patrice A Mawa; Moses Kizza; Nancy Lyadda; Margaret Nampijja; Alison M Elliott
Journal:  Vaccine       Date:  2012-01-31       Impact factor: 3.641

9.  Persistence of the immune response induced by BCG vaccination.

Authors:  Rosemary E Weir; Patricia Gorak-Stolinska; Sian Floyd; Maeve K Lalor; Sally Stenson; Keith Branson; Rose Blitz; Anne Ben-Smith; Paul E M Fine; Hazel M Dockrell
Journal:  BMC Infect Dis       Date:  2008-01-25       Impact factor: 3.090

10.  Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.

Authors:  Ansar A Pathan; Clare R Sander; Helen A Fletcher; Ian Poulton; Nicola C Alder; Natalie E R Beveridge; Kathryn T Whelan; Adrian V S Hill; Helen McShane
Journal:  PLoS One       Date:  2007-10-24       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.